{"id":389011,"date":"2024-12-19T00:00:00","date_gmt":"2024-12-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0017-2024-biopharma-hepatocellular-carcinoma-disease-landscape-forecast-g7-2024\/"},"modified":"2026-03-31T10:27:39","modified_gmt":"2026-03-31T10:27:39","slug":"dlsfon0017-2024-biopharma-hepatocellular-carcinoma-disease-landscape-forecast-g7-2024","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0017-2024-biopharma-hepatocellular-carcinoma-disease-landscape-forecast-g7-2024\/","title":{"rendered":"Hepatocellular Carcinoma | Disease Landscape &#038; Forecast | G7 | 2024"},"content":{"rendered":"<p>The hepatocellular carcinoma therapy market is experiencing substantial growth. Angiogenesis inhibitors have played a central role in treating advanced disease, but the approval of immunotherapies such as atezolizumab (Roche \/ Genentech) plus bevacizumab, durvalumab with or without tremelimumab (AstraZeneca), nivolumab plus ipilimumab (Bristol Myers Squibb \/ Ono Pharmaceutical), and pembrolizumab (Merck &#038; Co.) is causing the market to undergo a significant shift. The label expansion of immune checkpoint inhibitors into the untapped early-stage setting and the anticipated entry of novel immune checkpoint inhibitor-based combinations will expand treatment options for hepatocellular carcinoma and drive robust sales growth.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>How big are the clinically and commercially relevant drug-treatable hepatocellular carcinoma populations?<\/li>\n<li>What is the current treatment landscape for hepatocellular carcinoma? What are interviewed experts\u2019 insights on current therapies?<\/li>\n<li>What are the most promising agents in the pipeline, and how will they shape the future of the hepatocellular carcinoma therapy market?<\/li>\n<li>What are the main drivers and constraints of the hepatocellular carcinoma market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Geography: <\/strong>United States, EU5, Japan.<\/p>\n<p><strong>Primary research: <\/strong>19 country-specific interviews with thought-leading medical oncologists \/ hepatologists. Supported by survey data collected for this and other Clarivate research.<\/p>\n<p><strong>Epidemiology: <\/strong>Diagnosed and recurrent incident cases of hepatocellular carcinoma by country, segmented by drug-treatable and drug-treated early, intermediate, and advanced disease and line of therapy.<\/p>\n<p><strong>Forecast: <\/strong>10-year, annualized, drug-level sales and patient share of key hepatocellular carcinoma therapies through 2033, segmented by brands \/ generics and epidemiological subpopulations.<\/p>\n<p><strong>Drug treatments: <\/strong>Coverage of key current and emerging therapies.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Key features<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389011","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hepatocellular-carcinoma","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389011","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389011\/revisions"}],"predecessor-version":[{"id":575860,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389011\/revisions\/575860"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389011"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}